araag2/NLI4PR huggingface dataset:
Clinical trial: Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency (NCT00004313)

Eligibility criteria:
PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Primary adrenal insufficiency (Addison's disease) Serum
        dehydroepiandrosterone less than 0.5 nmol/L --Prior/Concurrent Therapy-- No concurrent
        investigational drug Stable glucocorticoid/mineralocorticoid dose over past year required
        --Patient Characteristics-- Hepatic: No hepatic disease Cardiovascular: No vascular disease
        No thrombotic disorder No angina No elevated blood pressure on 2 readings taken 15 minutes
        apart in 1 visit, i.e.: Systolic greater than 165 mm Hg OR Diastolic greater than 95 mm Hg
        Other: No clinically significant medical abnormality No gallbladder disease No malignancy
        No estrogen- or androgen-dependent neoplasia Benign prostatic hyperplasia eligible No other
        endocrine disease Controlled thyroid disease with normal thyroid-stimulating hormone
        eligible Mammogram required within 1 year prior to entry for women aged 40 and over No
        clinically significant abnormality No undiagnosed vaginal or uterine bleeding within 6
        months prior to entry Pap smear required within 1 year prior to entry No dysplasia
        (squamous intraepithelial lesion low-grade or higher)
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Patient description (medical language): A 33-year-old woman comes to clinic complaining of progressive fatigue, decreased appetite, and 11-lb weight loss in the past 2 months.  She uses levothyroxine because of the previously diagnosed Hashimoto disease. She has no other medical conditions and does not use tobacco, alcohol, or illicit drugs.  Physical examination shows a generalized increase in pigmentation of the skin.  Measurement of serum cortisol before and after administration of exogenous adrenocorticotropic hormone (ACTH) shows no difference in the levels. Stable glucocorticoid replacement therapy starts for her with the diagnosis for primary adrenal insufficiency (Addison disease)

Patient description (patient's own words): I went to the clinic because I was really suffering from fatigue and decreased appetite and I also lost 11 pounds over the past two months. I'm just 33 years old so that's not normal, especially for a woman. I take levothyroxine because I have been diagnosed with Hashimoto disease. I don't have any other medical condition, and I don't smoke I don't drink, and I don't do drugs. They also did my physical examination and they saw that I had an increase in pigmentation of my skin. They measured my cortisol level before and after giving me some ACTH hormone, and the results came back with no difference whatsoever. The doctor told me I have Addison disease and put me under glucocorticoid therapy.

Does the patient match the trial criteria? Entailment
Clinical trial: Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls (NCT02397200)

Eligibility criteria:
Inclusion Criteria:

          -  Girls aged ≥9 years old

          -  Prepubertal - Tanner stage 1. (gonadarche) Breast at Tanner stage 1)

          -  Height and weight ≤ 10th percentile for age and gender.

          -  Height-SDS ≥ -2.5 SDS

          -  BMI-SDS>-2 SDS

          -  Low proportion between weight and height

          -  Signing inform consent forms

        Exclusion Criteria:

          -  Diagnosis of Growth Hormone (GH) Deficiency or treatment with GH

          -  Any known chronic disease or dysmorphic syndrome including: bone diseases, organic
             brain diseases, neurological disease, past or current malignancy, chronic cardiac,
             renal or pulmonary problems

          -  Any known gastrointestinal disease including malabsorption

          -  Any known organic reason for growth retardation

          -  Any chronic treatment with medication that might affect appetite, weight or growth
             (for example SSRI's).
Female
No healthy subjects accepted to join the trial.
Subject must be at least 9 Years old.
Subject must be at most 14 Years

Patient description (medical language): A 9-year-old girl is brought to the office for evaluation of short stature and overweight body habitus. The patient's mother and father are 170 cm and 181 cm tall, respectively.  On physical examination, the patient's height is in the 5th percentile of her age.  Other findings include low-set ears, a high arched palate, a webbed neck, and cubitus valgus.  Chromosomal analysis reveals a 45, XO karyotype.

Patient description (patient's own words): I took my 9-year-old daughter to the doctor because my mother-in-law kept saying she seemed small and overweight. My husband and I are 170 cm and 181 cm tall, respectively. The physical health highlighted that she is in the 5th percentile of her age. The doctor said that she has low-set ears, a high-arched palate, a webbed neck, and cubitus valgus. She also did a chromosomal analysis, which revealed a 45, XO karyotype.

Does the patient match the trial criteria? Contradiction
Clinical trial: Azithromycin in Hospitalized COVID-19 Patients (NCT04359316)

Eligibility criteria:
Inclusion Criteria:

          -  Age ≥ 18

          -  COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed).

          -  Tympanic Temperature of ≥37.5 AND at least one of the following: Cough, Sputum
             production, nasal discharge, myalgia, headache or fatigue) on admission.

          -  Time of onset of the symptoms should be acute ( Days ≤ 10).

          -  SpO2 ≤ 93%

          -  Respiratory Rate ≥ 22

        Exclusion Criteria:

          -  Refusal to participate expressed by patient or legally authorized representative if
             they are present.

          -  Patients with prolonged QT or PR intervals, Second or Third Degree heart block and
             Arrhythmias.

          -  Patients using drugs with potential interaction with Azithromycin or
             Hydroxychloroquine.

          -  Pregnant or lactating women.

          -  History of alcohol or drug addiction in the past 5 years.

          -  Blood ALT/AST levels > 5 times the upper limit of normal on laboratory results.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Patient description (medical language): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient description (patient's own words): I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Does the patient match the trial criteria? Contradiction
Clinical trial: Risk Factors of Postoperative Complications in HCM Patients (NCT04275544)

Eligibility criteria:
Inclusion Criteria:

          -  Adult patients ≥18 years of age who underwent thoracotomy for septal myectomy.

        Exclusion Criteria:

          -  Patients with severe liver and renal disease, severe central nervous system disease,
             malignancy, defibrillators and age under 18 years old
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 100 Years

Patient description (medical language): A 23-year-old man comes to the emergency department following an episode of syncope.  He was working out when he felt dizzy and passed out without head injury.  He has had 3 other episodes of light-headedness over the last year, all happening during physical activity. He never had this experience while resting. He has no other medical conditions.  The patient does not use tobacco, alcohol, or illicit drugs.  His father died suddenly at age 35.  Vital signs are within normal limits.  On physical examination, the patient has a harsh systolic murmur.  The lungs are clear with no peripheral edema. Echocardiography shows asymmetric interventricular septal hypertrophy.

Patient description (patient's own words): I'm 23, and I got admitted to the ER because I fainted all of a sudden. I was in the gym, working out, when all of a sudden, I just got dizzy and passed out. Hopefully, I didn't hit my head. It's not my first time having that kind of dizziness at the gym, never when I'm chilling at home tho. I don't have any special medical conditions and I'm not even smoking, drinking or doing drugs! My dad died suddenly when he was 35, so I'm kind of scared. My vitals were normal while at the ER and they did a physical exam and they told me my heart sounds abnormal. My lungs are ok, but I had to do an echography of my heart, and they told me it is bigger than average.

Does the patient match the trial criteria? Entailment
Clinical trial: Reducing Length of Stay in the Emergency Department (NCT03185533)

Eligibility criteria:
Inclusion Criteria:

          -  the patients were registered in the ED from Jan, 2015 to Dec, 2015.

        Exclusion Criteria:

          -  the patients were excluded because of left without seeing a physician.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Patient description (medical language): A 23-year-old woman comes to the emergency department with a history of nosebleeds lasting for 1 hour. She has a history of heavy menses as well as occasional gum bleeding following dental procedures. Her mother also has a history of menorrhagia. Laboratory tests reveal increased bleeding time and slightly increased partial thromboplastin time. She has no other medical conditions and is otherwise healthy. Her coagulation study shows CB = 0.30 IU/mL and FVIII:C = 0.37 IU/mL. She is not smoking or using any kind of illicit drugs. She uses alcohol occasionally and is in ra elationship with her boyfriend for the past 2 years.

Patient description (patient's own words): I had to rush to the ER because of a non-stop nosebleed that had been on for 1 hour. As a 23-year-old, I always had heavy periods, and sometimes, my gums would bleed after going to the dentist or brushing my teeth. I thought that it was not very alarming since my mom also had heavy periods. I did some lab tests that showed that I had increased bleeding time and long clotting time. Otherwise, I'm pretty healthy, and I don't smoke or take any kind of drugs. I drink only at parties from time to time. I have been with my boyfriend for the last 2 years. I did a coagulation study and I got the following results: CB = 0.30 IU/mL and FVIII:C = 0.37 IU/mL.

Does the patient match the trial criteria? Entailment
Clinical trial: Movement Disorder Quantification Algorithm Development (NCT01534650)

Eligibility criteria:
Inclusion Criteria:

          -  Aged 18 years or older

          -  Clinical diagnosis of idiopathic Parkinson's disease or essential tremor

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Significant medical or psychiatric illness

          -  Not capable of following the required clinical instructions

          -  Serious medical conditions that compromise safety
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Patient description (medical language): A 60-year-old man comes to the clinic complaining of hand tremor that started few months ago.  It is most bothering when he wants to drink from a glass or pour from a bottle. He does not smoke, but drinks occasionally. He recently started consuming more alcohol as his tremor subsides somewhat when he drinks small amounts of alcohol.  Family history is significant for similar problems in his mother.  Vital signs are normal and the patient has no other medical conditions.  Neurologic examination shows bilateral tremor in the upper extremities. The diagnosis of essential tremor is confirmed.

Patient description (patient's own words): I'm only a 60 years old man but I already suffer from shaky hands. It started a few months ago, and it really bothers me when I want to pour myself a glass or even while drinking. I don't smoke, but I drink alcohol from time to time. To be honest, I've been drinking a little more lately since it helps me with the shaking. My mom had the same issue when she was my age. The doctor took my vitals, and they were normal. I don't have any other medical issues. I underwent neurological exams and it showed that I’m shaky from both sides. The doctor diagnosed me with essential tremor.

Does the patient match the trial criteria? Entailment
Clinical trial: Iron Status and Hypoxic Pulmonary Vascular Responses (NCT01847352)

Eligibility criteria:
Inclusion Criteria:

          -  Willing and able to give informed consent for participation in the study

          -  Men and women aged 18 years or older and generally in good health

          -  Detectable tricuspid regurgitation on echocardiography during both normoxia and
             hypoxia enabling measurement of pulmonary arterial pressure

          -  For iron-deficient volunteers: ferritin ≤15microg/L and transferrin saturation <16%

          -  For iron-replete volunteers: ferritin ≥20microg/L and transferrin saturation ≥20%

        Exclusion Criteria:

          -  Haemoglobin <8.0g/dl

          -  Haemoglobinopathy

          -  Iron overload defined as ferritin >300microg/L

          -  Hypoxia at rest or on walking (SaO2 <94%) or significant comorbidity that may affect
             haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a
             chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension,
             uncontrolled asthma or chronic obstructive pulmonary disease

          -  Exposure to high altitude (>2,500m) within the previous six weeks or air travel >4
             hours within the previous week

          -  Iron supplementation or blood transfusion within the previous 6 weeks

          -  Pregnancy or breast feeding
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Patient description (medical language): A 51-year-old man comes to the office complaining of fatigue and some sexual problems including lack of libido. The patient doesn't smoke or use any illicit drug.  Blood pressure is 120/80 mm Hg and pulse is 70/min.  Oxygen saturation is 99% on room air.  BMI is 24 kg/m2.  Skin examination shows increased pigmentation. Genotype testing is consistent with homozygosity for the C282Y mutation. Laboratory study shows transferrin saturation of 55% and serum ferritin of 550 μg/L. He is diagnosed as a case of hemochromatosis.

Patient description (patient's own words): I am 51 years old and I just came back from the doctor's office. I'm sick and tired of being that exhausted, reaching the point where me and my lovely wife are not touching each other anymore! I'm not smoking or doing drugs! My blood pressure was 120/80 mm Hg, and pulse was 70/min and my oxygen saturation 99%. My BMI is 24. My skin also turned a bit darker lately. He tested my genes and told me that I have a mutation of the C282Y gene. I also did lab tests where my transferrin saturation was 55% and serum ferritin was 550  μg/L. The doctor diagnosed me with iron overload.

Does the patient match the trial criteria? Contradiction
Clinical trial: An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome (NCT01013480)

Eligibility criteria:
Inclusion Criteria:

          -  Have completed all scheduled visits in protocol 22001 and have shown they can
             adequately follow the protocol, with sufficient medical justification to continue on
             open-label treatment with STX209, as assessed by the principal investigator

        Exclusion Criteria:

          -  Subjects with a medical condition that might interfere with the conduct of the study,
             confound interpretation of the study results, or endanger their own well-being.

          -  The occurrence or continuation of any adverse event or condition during study 22001
             that, in the opinion of the Investigator, should exclude the subject from
             participating in this open-label extension.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 6 Years old.
Subject must be at most 40 Years

Patient description (medical language): A 15-year-old boy with mild intellectual disability is brought to the office by his parents for a routine physical examination.  The boy is going to a school for students with learning disabilities.  The patient was adopted, and his immunizations are up to date.  Review of the patient's medical records is notable for cytogenetic studies that showed a small gap near the tip of the long arm of the X chromosome, which is consistent with fragile X syndrome, an X-linked disorder. The defect is an unstable expansion of trinucleotide repeats (CGG) in the fragile X mental retardation 1 (FMR1) gene, located on the long arm of the X chromosome. He is not using any medications and vital signs are within normal levels. His blood chemistry analysis as bellow:
Blood Chemistry Value      Normal Range     Patient Value
Glucose                    90-120 mg/dl     95 mg/dl
BUN (Blood Urea Nitrogen)  7-24 mg/dl       10 mg/dl
Creatinine                 0.7-1.4 mg/dl    0.8 mg/dl
Calcium                    8.5-10.5 mg/dl   9 mg/dl
Sodium                     134-143 mEq/L    135 mEq/L
Potassium                  3.5-4.5 mEq/L    3.7 mEq/L
Chloride                   95-108 mEq/L     98 mEq/L
CO2                        20-30 mEq/L      25 mEq/L
Blood pH                   7.38-7.42        7. 39

Patient description (patient's own words): My husband and I brought our 15-year-old son to the clinic for his routine exam. My son is going to school for special needs students. We adopted him a few years ago. His vaccinations are up to date. He already passed some chromosome testing and they found that he has a fragile X syndrome. The doctor told us that it comes from repeats in the fragile X chromosome. My son is not using any medication and his blood pressure temperature and breathing were normal during the exam. He also did a blood test. The results came back and showed that his blood sugar urea creatinine calcium sodium potassium chloride CO2 and blood pH were all within the normal range.

Does the patient match the trial criteria? Entailment
Clinical trial: An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen (NCT00320580)

Eligibility criteria:
Inclusion Criteria:

          -  Patients in good health as confirmed by medical history

          -  not pregnant as demonstrated by negative urine pregnancy test

          -  completed their last term pregnancy at least 42 days prior to Screening and at least
             one normal menstrual period since last pregnancy

          -  not lactating

          -  post-menarcheal and pre-menopausal

        Exclusion Criteria:

          -  History or presence of disorders commonly accepted as contraindications to steroid
             hormonal therapy including but not limited to the following - active or history of
             deep vein thrombophlebitis or thromboembolytic disorders or hypercoagulation
             disorders, cerebral vascular or coronary artery disease, uncontrolled hypertension, or
             migraines with focal aura, benign or malignant liver tumor which developed during the
             use of oral contraceptives or estrogen-containing products

          -  treatment with continuous oral contraception within three months of study

          -  previous use of contraceptive patch including norelgestromin/ethinyl estradiol

          -  patients who are amenorrheic (abnormal suppression or absence of menstruation)

          -  recent history of alcohol or substance abuse

          -  skin conditions resulting in oily, irritated or damaged skin at potential sites of
             application
Female
Accepts Healthy Volunteers
Subject must be at least 18 Years old.
Subject must be at most 45 Years

Patient description (medical language): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient description (patient's own words): I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Does the patient match the trial criteria? Contradiction